Swiss National Bank Buys 364,000 Shares of Kenvue Inc. $KVUE

Swiss National Bank increased its position in Kenvue Inc. (NYSE:KVUE) by 6.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 5,622,946 shares of the company’s stock after purchasing an additional 364,000 shares during the quarter. Swiss National Bank’s holdings in Kenvue were worth $96,940,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. increased its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue during the fourth quarter worth approximately $26,000. MV Capital Management Inc. acquired a new position in shares of Kenvue during the fourth quarter worth approximately $28,000. Reflection Asset Management bought a new position in shares of Kenvue in the 4th quarter worth $32,000. Finally, SBI Securities Co. Ltd. grew its position in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent research reports. UBS Group boosted their target price on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday. Barclays dropped their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen raised Kenvue to a “buy” rating in a report on Sunday, July 12th. Finally, Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.50.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.59% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $19.00 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The business has a fifty day simple moving average of $18.23 and a two-hundred day simple moving average of $17.87. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The company has a market capitalization of $36.47 billion, a P/E ratio of 22.35, a P/E/G ratio of 1.44 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter last year, the company earned $0.24 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. On average, analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.